Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CQ0Z
|
|||
| Former ID |
DNC001108
|
|||
| Drug Name |
Penfluridol
|
|||
| Synonyms |
PENFLURIDOL; 26864-56-2; Semap; 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol; TLP-607; McN-JR-16,341; 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol; Penfluridolum [INN-Latin]; C28H27ClF5NO; UNII-25TLU22Q8H; R 16341; EINECS 248-074-5; R-16341; BRN 1558826; CHEMBL47050; 25TLU22Q8H; MDLAAYDRRZXJIF-UHFFFAOYSA-N; 4-Piperidinol, 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)-; 4-Piperidinol,; Hydroxamates
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H27ClF5NO
|
|||
| Canonical SMILES |
C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
|
|||
| InChI |
1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2
|
|||
| InChIKey |
MDLAAYDRRZXJIF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 26864-56-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980270, 8173216, 10516385, 14811772, 17396800, 29217623, 34675416, 47657070, 48253912, 50017916, 50779938, 57311547, 85209831, 91011850, 92714229, 103225238, 103935800, 104316523, 109613031, 117504384, 118844612, 121362292, 125346580, 126624314, 126655552, 128579811, 131308149, 134223823, 134340092, 134340348, 134997989, 135684240, 136375687, 136946540, 137001487, 143493299, 144075917, 144115324, 144207095, 152240781, 162036329, 162175090, 163124133, 164175196, 164178159, 164780216, 165235791, 170466197, 172090925, 172863489
|
|||
| ChEBI ID |
CHEBI:92278
|
|||
| SuperDrug ATC ID |
N05AG03
|
|||
| SuperDrug CAS ID |
cas=026864562
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Blocker | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Type II diabetes mellitus | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| GABA-B receptor II signaling | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | NCAM signaling for neurite out-growth | |||
| Nicotine Activity on Chromaffin Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.